Evidence map›Paper›PMID 25223419›Full record

ArticleJournal of pharmaceutical sciences2014

In vitro evaluation of cenderitide-eluting stent I -an antirestenosis and proendothelization approach.

Xu Wen Ng, Yingying Huang, Kerh Lin Liu, Soon Ghim Lim, Horng Haur Chen, John C Burnett, Yin Chiang Freddy Boey, Subbu S Venkatraman

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. In vivo Evaluation of Cenderitide-Eluting Stent (CES) II.Annals of biomedical engineering · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xu Wen NgSchool of Materials Science and Engineering, Nanyang Technological University, Singapore 639798, Singapore.
Yingying HuangSchool of Materials Science and Engineering, Nanyang Technological University, Singapore 639798, Singapore.
Kerh Lin LiuSchool of Materials Science and Engineering, Nanyang Technological University, Singapore 639798, Singapore.
Soon Ghim LimSchool of Materials Science and Engineering, Nanyang Technological University, Singapore 639798, Singapore.
Horng Haur ChenDivision of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905.
John C BurnettDivision of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905.
Yin Chiang Freddy BoeySchool of Materials Science and Engineering, Nanyang Technological University, Singapore 639798, Singapore.
Subbu S VenkatramanSchool of Materials Science and Engineering, Nanyang Technological University, Singapore 639798, Singapore. Electronic address: assubbu@ntu.edu.sg.

Funding

Cardiovascular Peptides and Myocardial InfarctionR01HL083231 · NHLBI · MAYO CLINIC ROCHESTER · PI BURNETT, JOHN C, CHEN, HORNG H · 2006 to 2016
$4.6M
NHLBI NIH HHS R01 HL083231
6 · The paper itself

Abstract

Despite the success that drug-eluting stents (DESs) have achieved for minimizing in-stent restenosis (ISR), the antirestenotic agents used in DES have been implicated in delayed endothelial healing and impairment of endothelial functions. Cenderitide (CD-NP) is a novel antiproliferation chimeric peptide of semiendothelial origin; thus, this paper aims to demonstrate the selectivity aspect of this new peptide via in vitro evaluation on key players in ISR-smooth muscle cells (SMCs) and endothelial cells. The microbicinchoninic acid protein assay was used to investigate the CD-NP release from films and stents. Cenderitide-containing films blended with poly(ethylene glycol) and its copolymer exhibited higher release kinetics compared with neat poly(ε-caprolactone) (PCL) formulation. Cenderitide-eluting stents (CES) was produced by coating bare metallic stents with CD-NP entrapped PCL using an ultrasonic spray coater. The investigation of CD-NP on in vitro cells revealed that CD-NP inhibits human coronary smooth muscle cells (HCaSMCs) proliferation but exhibits no effects on human umbilical vein endothelial cells (HUVECs) proliferation. Moreover, CD-NP released up to 7 days displayed inhibitory effects on SMCs proliferation. The CES produced in this work shows that the released CD-NP inhibits HCaSMCs proliferation but did not hamper HUVECs proliferation in vitro, suggesting that it has potential to reduce ISR without retarding the endothelialization healing in vivo.

Indexed as

Drug CarriersDrug-Eluting StentsCardiovascular AgentsCell ProliferationCoronary RestenosisCoronary VesselsDelayed-Action PreparationsDrug StabilityHumansHuman Umbilical Vein Endothelial CellsKineticsMaterials TestingMetalsMuscle, Smooth, VascularMyocytes, Smooth MuscleNatriuretic PeptidesCardiovascular AgentscenderitideDelayed-Action PreparationsDrug CarriersMetalsNatriuretic PeptidespolycaprolactonePolyestersPolyethylene GlycolsSnake Venomsbiodegradable polymerbiomaterialsCD-NPcontrolled releaseexcipientsformulationnatriuretic peptidepeptide delivery

Identifiers

PMID25223419
PMCPMC4620572

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.